TARA vs TECX

Protara Therapeutics, Inc. vs Tectonic Therapeutic, Inc. — Valuation Comparison 2026

TARA

Biological Products, (No Diagnostic Substances)
Protara Therapeutics, Inc.
Quality
4.1
out of 10
Value Trap
30
LOW
Price
$4.65
Last close
Models
7/13
Active
VS

TECX

Biological Products, (No Diagnostic Substances)
Tectonic Therapeutic, Inc.
Quality
4.3
out of 10
Value Trap
18
SAFE
Price
$31.16
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType TARA Fair ValueTARA Upside TECX Fair ValueTECX Upside
Bayesian DCF Intrinsic $1.45 -68.8% $14.60 -53.2%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $2.67 -42.6% $18.11 -41.9%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for TARA vs TECX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

TARA vs TECX — Which Stock Is More Undervalued?

TECX scores higher with a 4.3/10 quality rating vs TARA's 4.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Protara Therapeutics, Inc. (TARA) and Tectonic Therapeutic, Inc. (TECX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

TARA currently trades at $4.65 with a QOC of 4.1/10, while TECX trades at $31.16 with a QOC of 4.3/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).